{"disease":{"id":"huntington-s-disease","name":"huntington s disease"},"drugs":{"marketed":[{"drug_id":"valbenazine","indication_name":"Chorea Associated with Huntington’s Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ingrezza","generic_name":"valbenazine","company_name":"Neurocrine","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2, Synaptic vesicular amine transporter, Synaptic vesicular amine transporter","drug_class":"","quality_score":55,"revenue":"1900","mechanism":null},{"drug_id":"deutetrabenazine","indication_name":"Chorea associated with Huntington’s disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Austedo","generic_name":"DEUTETRABENAZINE","company_name":"Teva","drug_phase":"marketed","molecular_target":"Synaptic vesicular amine transporter","drug_class":"","quality_score":70,"revenue":"1100","mechanism":"Austedo works by binding to the synaptic vesicular amine transporter, reducing the release of dopamine and other neurotransmitters."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06203106","title":"NYSCF Scientific Discovery Biobank","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"New York Stem Cell Foundation Research Institute","has_results":false},{"nct_id":"NCT02855476","title":"HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT03233646","title":"Retinal Imaging in Neurodegenerative Disease","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT06539169","title":"FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"xCures","has_results":false},{"nct_id":"NCT03761849","title":"A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":899,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT00665223","title":"A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":437,"lead_sponsor_name":"Teva Branded Pharmaceutical Products R&D, Inc.","has_results":true},{"nct_id":"NCT02006472","title":"A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":408,"lead_sponsor_name":"Prilenia","has_results":true},{"nct_id":"NCT02215616","title":"A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":352,"lead_sponsor_name":"Teva Branded Pharmaceutical Products R&D, Inc.","has_results":true},{"nct_id":"NCT00491842","title":"Individuals Patterns of Disclosure About Huntington s Disease (HD) and the Association With Adaptation to HD","phase":"","overall_status":"COMPLETED","enrollment_count":315,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT02494778","title":"A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":248,"lead_sponsor_name":"Prilenia","has_results":true},{"nct_id":"NCT03628235","title":"HD-Charge: Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":233,"lead_sponsor_name":"CHDI Foundation, Inc.","has_results":false},{"nct_id":"NCT05107128","title":"A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":189,"lead_sponsor_name":"Supernus Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02342548","title":"Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":188,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05655520","title":"A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":153,"lead_sponsor_name":"Supernus Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02507284","title":"Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":106,"lead_sponsor_name":"Azevan Pharmaceuticals","has_results":true},{"nct_id":"NCT05943054","title":"Striatum and Hippocampus on Different Time Scales","phase":"NA","overall_status":"UNKNOWN","enrollment_count":104,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03664804","title":"Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT03225846","title":"Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":88,"lead_sponsor_name":"Wave Life Sciences Ltd.","has_results":true},{"nct_id":"NCT02881931","title":"FuRST 2.0 Cognitive Pre-Testing","phase":"","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"CHDI Foundation, Inc.","has_results":false},{"nct_id":"NCT06585449","title":"A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":66,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT03225833","title":"Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":61,"lead_sponsor_name":"Wave Life Sciences Ltd.","has_results":true},{"nct_id":"NCT00652457","title":"Study of Memantine to Treat Huntington's Disease","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Jody Corey-Bloom, MD, PhD","has_results":true},{"nct_id":"NCT02819700","title":"Evaluation and Characterization of Behavioural Disorders and Dementias by the Behavioural Dysexecutive Syndrome Inventory (BDSI)","phase":"","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Centre Hospitalier Universitaire, Amiens","has_results":false},{"nct_id":"NCT02519036","title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03342053","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT02956148","title":"Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"CHDI Foundation, Inc.","has_results":false},{"nct_id":"NCT05126862","title":"Measurement and Modification of Threat Interpretation Bias in Neurodegenerative Movement Disorders (Aims 2 & 3)","phase":"NA","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"University of Virginia","has_results":true},{"nct_id":"NCT06807892","title":"Comparison of Two Cognitive-Motor Rehabilitation Approaches Via Exergames: a Study of Cognitive, Motor and Behavioral Functions in Huntington's Disease Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"University Hospital, Angers","has_results":false},{"nct_id":"NCT05707663","title":"Longitudinal Assessment of Brain Structure and Function in Juvenile-onset Huntington's Disease","phase":"","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"University of Iowa","has_results":false},{"nct_id":"NCT07246941","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT07536061","title":"A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":32,"lead_sponsor_name":"Sarepta Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02990676","title":"Exploring Computerised Cognitive Training for People With Huntington's Disease","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Cardiff University","has_results":false},{"nct_id":"NCT02509793","title":"A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"William Ondo, MD","has_results":false},{"nct_id":"NCT06828471","title":"Social Cognition Training in Individuals With Huntington's Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Rush University Medical Center","has_results":false},{"nct_id":"NCT02231580","title":"Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":17,"lead_sponsor_name":"Ipsen","has_results":true},{"nct_id":"NCT03306888","title":"Feasibility and Acceptability of Implementing a Clinic-based Physical Activity Coaching Intervention in People With Premanifest and Early Stage HD","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Teachers College, Columbia University","has_results":false},{"nct_id":"NCT04000594","title":"A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT03886753","title":"Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products","phase":"","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":false},{"nct_id":"NCT07299682","title":"Facilitating Effective Eating With DoddleBags: A Single-Arm Acceptability Study Of DoddleBags to Assess Impact on Self Feeding Behaviours in a Huntington's Disease Population","phase":"NA","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"University of Hull","has_results":false},{"nct_id":"NCT05773196","title":"Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study","phase":"","overall_status":"RECRUITING","enrollment_count":5,"lead_sponsor_name":"Sanguine Biosciences","has_results":false}],"total":40},"guidelines":[],"source":"Drug Landscape verified database"}